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Introduction
Early detection and new therapeutic approaches drasti-
cally improve cure and progression-free survival of tumor-
bearing patients. In general, a detectable primary tumor is 
treated by chemotherapy, surgery, and/or radiation leading 
to its elimination from the patient or reduction in size to a 
few viable cells. However, survival of a small number of 
malignant cells, the so-called “minimal residual disease”, 
might arise for diverse reasons, including an incomplete 
surgical excision for impossible diagnosis of too small 
clusters of cells. Furthermore, tumor cells might survive to 
chemotherapeutic and radiotherapeutic treatments, depend-
ing on the variability of cell cycle length and phase of 
each single cell, or depending on the expression of a drug 
resistant phenotype. Surviving cells may have different 
fates, consisting of starting again to grow or entering into 
a “dormant state”. Thus, it is possible for tumor cells to 
persist for extended periods until the host dies. Otherwise, 
after a prolonged period of time corresponding to clinical 
remission, tumor cell can give rise to a secondary lesion. 
Those lesions may occur locally or at distant site from the 
pre-existing primary tumor and are known as organ metas-
tasis. The emergence of metastasis is, indeed, the most 
dangerous event during the natural history of the neoplas-
tic disease. Although only a minority of patients exhibit 
clinically detectable metastases at the time of diagnosis, 
metastases are responsible for more than 90% of patient 
mortality. Metastatic lesions result from a multistep process 
that involves progression of tumor cells into primary host 
tissues, intravasation into altered tumoral blood vessels, 
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and dissemination to distant organs, and extravasation and 
growth after adaptation into the foreign tissue microenvi-
ronment. The term “dormancy” indicates the length of 
time needed to metastatic cells for adaption to secondary 
organs [1]. Clinical observations report that melanoma, 
breast, and prostate tumors may relapse into target organs 
many years or decades after apparent curative treatment of 
primary tumor. This is possible because tumor cells spread 
to distant organs earlier than we may expect and survive 
in the hostile new microenvironments. Isolation of dis-
seminated tumor cells in the blood by liquid biopsy may 
help to prevent and combat this behaviour. Other clinical 
reports describe extraordinarily long remissions following 
surgical treatment of intraocular melanoma, testicular tera-
toma, osteogenic sarcoma, and renal carcinoma [2]. Dur-
ing the dormant state, tumor cells survive in the host tis-
sues remaining confined in a low proliferating or quiescent 
state, resisting to drugs and immune attacks, until being 
recruited into a high proliferation compartment by either 
genetic or epigenetic changes. Dormancy may be sus-
tained by limited blood supply; this condition of low oxy-
gen and reduced nutrients determines an absolute increase 
of tumor cells number very close to zero, since the number 
of dividing cells may equate the number of dying cells [3, 
4]. It is important to remember that many of the mecha-
nisms proposed to explain dormancy have been identified 
using experimental models, although all are very plausible, 
up to now are not completely confirmed in tumor-bearing 
patients [1]. Thus, it is important to introduce new hypoth-
eses and offer new tools to improve knowledge regard-
ing tumor dormancy, to translate these new advances into 
clinic.
This review discusses the relevance of a particular aspect 
of tumor microenvironment, participating in harbouring 
dormant tumor cells, either from primary or secondary 
lesions. The aspect of tumor microenvironment which we 
are interested to introduce in the complex scenario of dor-
mancy is represented by the extracellular acidosis, which 
frequently characterizes solid tumors.
Why tumor microenvironment is often 
characterized by low pH
Tumor cells, even when there is enough  O2 to support 
mitochondrial function, use glycolysis to sustain their 
high proliferation rate, the so-called “Warburg effect” [5, 
6]. This phenomenon was first reported by O.H. Warburg 
in the 1920s, and although the “Warburg hypothesis” of 
impaired mitochondrial metabolism has proven to be incor-
rect, an increased conversion of glucose to lactic acid and 
 H+ in tumors has been constantly demonstrated. “Aero-
bic glycolysis” leads to the conversion of one molecule 
of glucose into two molecules of lactic acid and 2  H+ to 
produce 2 ATP, compared to the 36 ATP produced by oxi-
dative metabolism [5, 6]. Thus, ATP generation from gly-
colysis is far less efficient, although rapidity of this path-
way might represent a compensatory aspect. Furthermore, 
tumor cells implement glycolysis promoting an abnormal 
high rate of glucose uptake [7] trough the up-regulation 
and the enhanced activity of glucose transporters. The 
increased glucose uptake is useful for diagnostic purposes, 
as in the case of monitoring uptake of glucose analogue 
tracer (18F)-fluoro-2-deoxy-d-glucose (18FdG) by positron-
emission tomography (PET) [8]. PET imaging of tumor-
bearing patients has shown that numerous, although not all, 
primary and metastatic lesions express a significant glucose 
uptake.
Aerobic glycolysis up-regulation in malignant phe-
notype, that is mostly due to stable genetic or epigenetic 
changes [5], is important for proliferating tumor cells 
since glucose can be diverted into macromolecular precur-
sors. Indeed, glucose 6-phosphate is used for glycogen and 
ribose 5-phosphate biosynthesis, dihydroxyacetone phos-
phate for triacylglycerol and phospholipid synthesis, and 
pyruvate for alanine and malate synthesis. Furthermore, the 
isoform of pyruvate kinase M2, usually highly expressed in 
tumor cells under activity of oncogenic transcription factor 
c-MYC, may slow down aerobic glycolysis, which results 
into accumulation of up-stream precursors for anabolic 
demand of proliferating cells [9]. c-MYC is also involved 
in promotion of many of glycolytic enzymes [10], together 
with Akt pathway, which enhances glycolysis through acti-
vation of hexokinase 2, phosphofructokinase 1 and 2 and 
expression of glucose transporters [11–13]. The generated 
pyruvate, together with the entry of glutamine into tricar-
boxylic acid (TCA) cycle, cooperates to the promotion 
of anabolic reactions needed for cell division. Thus, an 
enhanced lactic acid production during a high rate of pro-
liferation is difficult to imagine, and only when uptake of 
glucose superimposes anabolic biomass formation, lactic 
acid starts to accumulate and extracellular pH reduces. A 
high glycolytic rate has an additional advantage for prolif-
erating tumor cells, that is the reduction of radical oxidative 
substances and the related cytotoxic effects [14].
When oxygen tension decreases and a hypoxic micro-
environment develops, stabilization of hypoxia induc-
ible factor 1α (HIF-1α) transcription factor may regulate 
an elevated number of genes driving tumor cells metabo-
lism toward an anaerobic glycolysis pathway. Such genes 
include glucose transporters (GLUT1 and 3) [15], gly-
colytic enzymes (Hexokinase I and II, phosphofructoki-
nase-1, aldolase-A and C, phosphoglycerate kinase 1, 
enolase-α), pyruvate dehydrogenase kinase 1 (PDK1, that 
inactivates the enzyme responsible for conversion of pyru-
vate to acetyl-CoA [16]), and genes for lactate production 
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(LDHA, encoding lactate dehydrogenase A, which converts 
pyruvate to lactate [17]) and for lactate extrusion (MTC-
4, the monocarboxylate transporter-4). Lactate production 
in hypoxic cancer cells is also enhanced by the increased 
expression of PKM2 [18] and activation of PDK1. PDK1 
suppresses pyruvate dehydrogenase (PDH) activity limit-
ing the entry of pyruvate into TCA cycle. Thus, pyruvate is 
mostly redirected into lactate and  H+ by LDH-A.
Therefore, to maintain an intracellular pH compatible 
with survival and/or proliferation, additional adaptations 
are required. The mechanism for long-term internal pH 
control is represented by promotion in tumor cells of mul-
tiple and redundant families of transporters, which release 
protons and lactate into extracellular environment, such as: 
 Na+/H+ exchanger 1 (NHE1),  HCO3− transporters  (Na+/
HCO3− co-transporters, NBCs and anion exchange pro-
tein 1, AE1), proton-linked monocarboxylate transporters 
(MCT1 and 4), and vacuolar  H+-ATPases (V-ATPases) 
[19]. In addition, carbonic anhydrases IX (CAIX), a 
hypoxia–inducible effector, participates to the complex 
machinery responsible of internal pH control favouring 
export of protons and import of bicarbonate ions [19].
On the whole, cancer cells that adapt their metabolism 
to different levels of oxygen caused by either dividing 
process or hypoxic condition produce a significant acidifi-
cation of the extracellular microenvironment. It is known 
that pH value of extracellular environment in several tumor 
histotype ranges from 6.7 to 7.1 [20]. Interestingly, extra-
cellular acidosis maintains a high level of CAIX expres-
sion in tumor cells, in a HIF-1α-independent way [21]. 
Furthermore, we cannot exclude that tumor extracellular 
acidity may also be supported by a poor blood perfusion 
and an uneven distribution of lymphatic vessels, frequently 
very poor in the core of the mass and more evident in the 
periphery. As a consequence, interstitial fluid pressure is 
maintained elevated. It is for these considerations that aci-
dosis of the extracellular space of tumors has been included 
among the most important hallmarks of tumor microenvi-
ronment [22].
How low pH may contribute to dormancy 
of tumor cells
Acidity induces a reduced proliferation, high resistance 
to apoptosis and autophagy
Whereas a coordinate series of events account for progres-
sion through the cell cycle in normal cells, in cancer cells, 
the deregulation of multiple control mechanisms results 
in different degrees of autonomy from growth-stimula-
tory or -inhibitory signals, making cancer cells adapted 
to grow quite indefinitely. However, proliferative rate of 
tumor cells may vary and non/slow-proliferating cells are 
common, which implies a high rate of cell death. Indeed, 
studies of human and animal tumors have demonstrated 
heterogeneity in mitotic index within different regions of 
the same tumor mass. The heterogeneity of cell prolifera-
tion is due to different factors, such as cell differentiation, 
variant generation with different proliferative rates, and 
availability of oxygen and nutrients (i.e., glucose, glu-
tamine, and branched-chain amino acids) in the microen-
vironment. Thus, slow-proliferating cells may occur in 
solid tumors and often are responsible for relapse, due to 
their high resistance to clinical treatments. In this context, 
acidic tumor microenvironment promotes in tumor cells a 
low-proliferating phenotype, which does not revert even in 
the presence of a high level of growth factors [23]. It has 
also been shown by several reports that extracellular aci-
dosis increases the percentage of cells in G0 phase [24]. 
Indeed, exposure to acidosis alters growth factor signaling 
and reduces serum ability to stimulate Raf/ERK/mTORC1 
kinase pathway [25]. Aguirre-Ghiso et al. showed that dor-
mancy in human head and neck cancer cells depends on 
the block of the Raf/ERK pathway together with the acti-
vation of p38 [26]. Besides, it was demonstrated that acid-
ity inhibits AMPK [27] driving a mitotic delay through a 
misoriented spindle due to improper astral microtubule-cell 
cortex interactions [28]; indeed, it is known that cell divi-
sion is achieved through a correct assembly, positioning, 
and orientation of the microtubule-based spindle. Extracel-
lular acidity modulates intracellular pH that in turn directly 
affects cell cycle. This is a quite common mechanism for 
cell proliferation control in both normal and cancer cells 
that was demonstrated several years ago [29]. When inter-
nal pH drops following a sustained extracellular acidosis, 
also G2/M entry is limited by a reduced cyclin-dependent 
kinase 1-cyclin B1 activity [30].
A recent study showed that transforming growth 
factor-β2 (TGFβ2) was effective in promoting the up-
regulation of p27 and p38 by the SMAD1/2/5 pathway in 
tumor cells undergoing a dormant state [31]. Lactic acid 
was shown to induce both transcription and protein secre-
tion of TGFβ2 in glioma cells [32] and to induce TGFβ1 
production in in vivo model [33]. More recently, we found 
that an acidic microenvironment is able to promote TGFβ 
secretion and signaling in mesenchymal stem cells (MSC), 
driving the progression to malignancy in a melanoma cell 
system [34] and suggesting that acidity is a strong inducer 
of TGFβ family members. Esomeprazole, a proton pump 
inhibitor activated by acidity, inhibited TGFβ expression in 
MSC grown in a low pH medium [34].
In addition, we have observed that a reduced pH pro-
motes in melanoma cells a typical epithelial-to-mesenchy-
mal transition (EMT) program characterized by a reduced 
level of proliferation, induction of several mesenchymal 
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markers, resistance to apoptosis and high metalloprotease-
dependent invasiveness [35]. Acidosis-exposed tumor cells 
were also able to favour in vivo organ colonization of intra-
venously injected non-acidic tumor cells, indicative of a 
new cooperation between tumor cell subpopulations [35]. 
We may suggest that acidic-adapted melanoma cells protect 
non-acidic cells from blood turbulence and possible inter-
actions with immune cells, and support survival and final 
lodgment in host microenvironment of secondary organ. 
Furthermore, acidity contributes to promote in melanoma 
cells an elevated resistance to pro-apoptotic agents [35] and 
resistance to apoptosis is well ascertained to be useful for 
dormant tumor cells. Additional evidences indicate that low 
pH activates MAPK signaling in a variety of tumor cells 
generating a protective effect against apoptosis induced 
by multiple cytotoxic stresses [36, 37]. Incubation of lym-
phoma cells in acidic conditions (pH 6.5) blocks apoptosis 
promoted by glucose or glutamine deprivation, a phenome-
non mediated by the acid-sensing G protein-coupled recep-
tor (GPR65) through an up-regulation of Bcl-2 and Bcl-xL 
factors [38]. Thus, it is possible that the reduction of tumor 
mass expansion during dormancy favoured by acidity will 
be a consequence of a delay of the cell cycle, rather than 
the induction of cell death.
Another aspect associated with EMT elicited in tumor 
cells by acidity is represented by their metabolic adapta-
tion. Acidic cancer cells switch from glycolysis to oxida-
tive phosphorylation (Oxphos) to favour a generation of 
more bioenergetic molecules instead of biomass for cell 
division [27, 39]. Metformin, a standard drug for diabetes, 
is a very efficient drug to kill acidic melanoma cells inhib-
iting their metabolic program [27]. The main energetic 
source of acidic pH-adapted cancer cells was identified to 
derive from fatty acid oxidation [40]. An acidic niche is 
able to preserve Oxphos metabolism in tumor cells also in 
high glucose, indicating the absence of Crabtree effect in 
acidic cells [41]. Oxphos metabolism might be convenient 
for dormant cells which need energy to survive and resist 
several stressors using alternative substrates. Furthermore, 
it has been observed that quiescent human leukaemia stem 
cells use Oxphos to produce the required energy [42].
Despite the liaison between acidic phenotype and 
stemness is still not completely clear, an indication of a pos-
sible connection can consist in the fact that EMT induces 
stem-like traits in different tumor types, such as mammary 
tumors [43] and head and neck squamous cell carcinoma 
[44]. Acidity, independently from a restricted oxygen ten-
sion, promotes stem cell markers and self-renewal in gli-
oma cells. Low pH exerts a promotion of glioma stem cells 
(GSC) through elaboration of HIF-2α-dependent angio-
genic factors. Induction of HIF-2α and other GSC markers 
by acidic stress can be reverted by pH elevation, suggesting 
that GSC phenotype might be targeted, raising pHe [45]. 
Lisanti et al. [46] found that ketones and lactate stimulate 
stem cell markers in breast carcinoma cells, expressing an 
oxidative mitochondrial metabolism. This suggests that an 
appropriate mitochondrial antagonist, such as metformin, 
could eradicate cancer stem cell subpopulation. Hirsch 
et  al. [47] showed that metformin selectively kills cancer 
stem cells isolated from breast cancer, and the combina-
tion between metformin and doxorubicin kills both cancer 
stem cells and non-stem cancer cells and prevents relapse 
much more efficiently than either drug alone in a xenograft 
mouse model. Quite recently, Petrachi et  al. demonstrated 
that phenphormin, but not metformin, is able to affect via-
bility and growth of melanoma cancer stem cells [48].
An additional tumor survival mechanism, also impor-
tant for dormancy, is autophagy. Autophagy is a catabolic 
process through which cellular metabolism is maintained 
recycling the self-digested cytoplasmic proteins and orga-
nelles. Low levels of autophagic activity are observed 
under physiological conditions, while in tumor cells, 
autophagy promotes cell survival during the frequent nutri-
ent restriction and hypoxia [49]. Autophagy was found to 
sustain the maintenance of cancer stem cell phenotype, and 
cooperates to chemo- and radio-resistance [50–53]. Inhibi-
tion of autophagy, on the contrary, increases chemo- and 
radio-sensitivity [54]. Acute and chronic exposure to low 
pH promotes high level of autophagic activity, and this 
sustains cell survival and aggressiveness, while the phar-
macological inhibition of autophagy in such acidic tumor 
cells reduces their ability to survive [55]. Furthermore, it 
was demonstrated that acidosis blocks the inhibitory activ-
ity of chloroquine on autophagy, thus chloroquine does not 
result effective in tumor treatment [56]. Up-regulation of 
autophagy-mediated degradation and recycling of cellu-
lar substrates by acidic cancer cells can support metabolic 
pathways considering that an acidic microenvironment is 
generally characterized by low nutrients and oxygen.
Finally, it seems reasonable to suggest that the pheno-
type acquired by acidic tumor cells results into several 
characteristics useful for a dormant state, such as low repli-
cation rate, high resistance to apoptosis and autophagy.
Acidity promotes invasion
Acid-activated tumoral catepsin L was reported to be able 
to amplify proteinase cascade through activation of urok-
inase-type plasminogen activator (uPA) [57], which con-
verts plasminogen to plasmin. This latter then degrades 
various components of the extracellular matrix (ECM), 
such as fibronectin, laminin, proteoglycan, and collagen 
[58], and activates latent collagenase and growth fac-
tors [59]. The concomitant expression of uPA and uPA 
receptor (uPAR) by tumor cells results in a high invasive 
capability [60]. uPAR is a glycosylphosphatidyl-inositol 
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(GPI)-anchored molecule, and therefore, it lacks trans-
membrane domains able to transfer extracellular signals 
to signaling pathways. Thus, uPAR must cooperate with 
cell membrane molecules able to confer signaling com-
petence on uPAR itself [61]. Upon interaction of α chain 
with uPAR, integrins α5β1 and αvβ3 can interact and 
activate Receptor Tyrosine Kinases (RTKs). Such inter-
action is potentiated by catalytic and non-catalytic uPA 
binding to uPAR and can induce RTKs activity even in 
the absence of the relevant ligand (EGF, PDGF, ILGF, 
and HGF) [61, 62] in an FAK-dependent manner [63]. In 
head and neck carcinoma, uPAR drives tumor growth by 
interacting with α5β1 integrin, a complex that activates 
focal adhesion kinase (FAK) and EGF receptor (EGFR), 
final effector of this mitogenic signal. Blocking uPAR, 
β1-integrin, FAK or EGFR, singly or in combination, 
results in tumor growth suppression and dormancy [1]. 
Indeed, it was reported that dormancy associates with 
a quite complete inhibition of the Raf-MEK-ERK path-
way as in quiescent cells [64]. Therefore, it is reasona-
ble that, even though uPAR is up-regulated in acidity, its 
mitogenic activity may be abrogated by loss of integrin 
interaction and/or reduction in EGFR cross talk. This last 
condition may leave uPAR to exert pro-invasive effects 
without promoting cell proliferation.
Furthermore, acid-activated cathepsin B and cathepsin-
activated uPA/plasminogen/plasmin axis activate secreted 
latent metallo-proteases (MMPs) by proteolytic cleavage. 
MMPs are a family of structurally related zinc-dependent 
endopeptidases, collectively capable of degrading all com-
ponents of ECM [65]. MMPs have long been associated 
with invasiveness, angiogenesis and tumor cell dissemina-
tion [66–68], due to their capacity to help tumor cells to 
cross-structural barriers, including basement membranes, 
to migrate into the blood, extravasate and colonize in dis-
tant host tissues. Kato et  al. have shown that, in mouse 
metastatic B16 melanoma cells, expression of MMP-9 
and in  vitro invasiveness is induced by acidic  pHe  (pHe 
5.4–6.5) [69]. Another component of basement membrane 
to be degraded by tumor cells to disseminate is the heparan 
sulphate chains. Toyoshima and Nakajima reported that 
heparanase has an optimal pH of 4.2, but a significant hep-
aranase activity persists at pH 6.0–6.5, suggesting that the 
acidic environment of tumors may activate the degrading 
properties of tumor heparanases [70].
When melanoma cells were exposed to acidic condition 
for long time and selected subpopulations were isolated, 
it was found that these tumor cells exhibit a high level of 
invasiveness and proliferation following re-exposure to 
physiological pH [71]. The high level of invasiveness and 
proliferation of acid-adapted tumor cells after exposure 
to the standard pH evokes the awaking of dormant tumor 
cells, invasion in local host tissues, and growth.
In contrast to the several findings on the positive rela-
tionship between acidity and invasiveness, it is still under 
debate whether low pH may promote motility, the so-called 
amoeboid style of migration. Stock et  al. using a model 
of directional cell migration in an extracellular pH gradi-
ent showed that melanoma cells hardly migrate at pHe 
6.6 when adhesion was found particularly elevated [72]. 
Indeed, through computational molecular dynamic simu-
lations, Paradise et  al. found that acidic extracellular pH 
(pH 6.0 for 8 h) promotes opening of the αvβ3 headpiece 
[73], a conformational change supporting a stable interac-
tion between integrin αvβ3 and its ECM biological ligands. 
In accordance, we experienced that acidity-exposed mela-
noma cells reduce their ability to heal wounds, tested by 
scratch test analysis, and express a reduced capacity to 
cross filters of Boyden chambers. Only when we exposed 
melanoma cells to lactic acid, migration recovers the 
level of control melanoma cells grown in the standard pH 
medium, however, without exceeding it [27].
Acidity may participate to dormancy either conferring, 
during the initial period of adaptation of tumor cells into 
the foreign microenvironment, some invasive properties 
useful to lodge in new sites, or favouring growth into adja-
cent host tissues when some genetic or epigenetic changes 
induce relapse.
Acidity promotes angiogenesis
Regarding angiogenesis, it was demonstrated that a tran-
sient exposure of endometrial carcinoma cells to acidosis 
(8  h at pH 5.5) induced a preferential VEFG121 isoform 
up-regulation through p38 MAPK and SAPK/JNK path-
ways [74]. When human pancreatic adenocarcinoma cells 
were incubated for different periods at pH between 6.7 and 
7.4, it was found that the expression of VEGF was particu-
larly stimulated by a 6–8  h-pH 6.7–7.1 treatment. Acidic 
pH also simulates NF-kB binding activity to the NF-kB site 
of VEGF [75, 76]. NF-kB was also found responsible of 
acidic pH-induced transcriptional activation of IL-8 gene, a 
promoter of angiogenesis [77]. However, when breast car-
cinoma cells were exposed to a pH 6.7 for 18 h, there was 
a significant decrease in VEGF mRNA expression [78]. 
Acidosis may also play an inhibitory role on angiogen-
esis exerting a potent block on HIF-1α stabilization, a key 
hypoxia transcription factor involved in VEGF gene activa-
tion [79]. Thus, angiogenesis regulation by pH might be 
either tissue specific or time of exposure-dependent, con-
sidering that acute acidosis stimulates, whereas a chronic 
exposure inhibits VEGF.
By studying acidosis-induced signalings in tumor cells, 
we observed that extracellular acidity (pH 6.7 ± 0.1) stim-
ulates the expression and secretion of lymphangiogenic 
growth factor C (VEGF-C) by melanoma cells, mediated 
 S. Peppicelli et al.
1 3
by NF-κB transcription factor activity [80]. We also dem-
onstrated that esomeprazole, a proton pump inhibitor 
(PPI) activated by a low pH, inhibits VEGF-C expression 
in acidic melanoma cells down-regulating NF-κB [80]. 
VEGF-C, in addition to the well-known role of VEGF-A 
in relapse, might represent a new causal link between lym-
phangiogenesis, lymph node colonization, and progres-
sion [81]. Development of new lymphatic vessels might be 
also instrumental in reducing the high interstitial pressure 
expressed by certain tumor regions, favouring diffusion of 
macromolecules from blood vessels to tumor cells, which 
may relapse.
During a dormant period, quiescent or low-proliferating 
cells may take advantage to express a pro-angiogenic and/
or lymphangiogenic phenotype that an acidic microenvi-
ronment may stimulate to finely control level of nutrients.
Acidity favours escaping from immune surveillance
To explain time variability of dormant state, Aguirre-Ghiso 
JA has proposed three major mechanisms: cellular dor-
mancy, angiogenic dormancy, and immunosurveillance [1]. 
During cellular dormancy, tumor cells are G0–G1 arrested 
and they need to evade immune cell cytotoxicity to sur-
vive. Genetic modifications can re-activate a proliferative 
activity, even at low rate, in dormant cells. Despite this, 
the expansion of tumor lesion may not be reached, due to 
the effect of an active immune response and to the balance 
between pro- and anti-angiogenic. We believe that tumor 
microenvironment acidosis may sustain cellular dormancy, 
maintaining tumor cells unable to resume proliferation and 
hiding them from immune surveillance.
There is increasing evidence that cancer cells escape 
immune destruction by suppressing the anti-cancer immune 
response through maintaining a relatively low pH in their 
environment [82]. Indeed, the acquired acidic phenotype 
enables cancer cells to suppress the anti-cancer activity of 
immune cells promoting the secretion of chemokines to 
enhance T-regulatory recruitment or producing immuno-
suppressive cytokines [83]. Several studies have shown that 
acidic  pHe inhibits T-cell proliferation [84], dendritic cell 
maturation [85], cytotoxic T lymphocyte activity (CTLs) 
[86], lymphokine-activated killer cells [87], and natural 
killer (NK) activity and viability [88]. Furthermore, lower-
ing  pHe to 6.5 has been reported to lead to a loss of func-
tion of human and murine tumor-infiltrating T lymphocytes 
consisting in a significant impairment of cytolytic activity, 
cytokine secretion, and reduction of T-cell receptor and 
interleukin-2 α-chain receptor expression [89]. T-cell func-
tion was found to be completely restored buffering pH to 
a physiological value; however when exposure to an acidic 
microenvironment was sufficiently prolonged, such as a 
chronic exposure, T cells were deeply damaged and under-
went apoptosis [89].
Extracellular lactic acid generated by glycolytic cancer 
metabolism and accumulated in tumor microenvironment 
supports the suppressive effect on T-cell function exerted 
by low pH [83]. Mendler et  al. identified that tumor lac-
tic acidosis suppresses CTL functions via inhibition of p38 
and JNK/c-Jun activation [90] and Fisher et  al. demon-
strated that lactic acid inhibits T-cell proliferation in a dose-
dependent manner, whereas sodium lactate, which does not 
lead to an acidification of the medium, had no suppressive 
effect [84]. Moreover, prolonged incubation with high dose 
of lactic acid (20 mM) was shown to induce CTL death of 
up to 60%, while exposure to the same low pH, derived 
from HCl addition to the medium, was less effective. It has 
also been demonstrated that lactic acid generated by can-
cer cells promotes tumor development by inhibiting the 
immune response increasing arginase-1 (ARG1) expression 
and inducing IL-23/IL-17 secretion by tumor-associated 
macrophages (TAMs) of M2 phenotype [91]. Indeed, tran-
sient exposure of cells to acidic pH suppresses the ability of 
macrophages to mount an adequate antibacterial response 
elicited by Toll-like receptor 2 and 4 activation [92].
Recent studies indicate that buffering low pH at the 
tumor site by in  vivo administration of esomeprazole, a 
PPI, improves tumor-infiltrating lymphocyte effector func-
tions in melanoma lesions and delays cancer progression 
in tumor-bearing mice [89, 93]. Inhibition of proton pumps 
on tumor cells with pantoprazole, another PPI, hampers 
tumor-induced suppression of macrophages both in  vitro 
and in  vivo [94, 95]. Finally, neutralization of tumor pH 
with bicarbonate impairs the growth of cancer in mice, and 
this effect was associated with an increased T-cell infiltra-
tion in tumor masses [96].
Overall, several evidences sustain that low pH might 
provide an immunological privileged niche functional for 
cellular dormancy of quiescent tumor cells.
Acidity promotes resistance to drug 
and radio‑treatment
Acidosis is able to influence the resistance of tumor cells 
to anticancer therapy [97], one of the major obstacle dur-
ing chemotherapeutic treatment of solid tumors [98]. Cel-
lular drug uptake and intracellular targeting are key factors 
for a successful anticancer treatment and both mechanisms 
are influenced by  pHe. Extracellular acidity reduces the 
intracellular concentration of chemotherapeutic agents, 
mainly weak base drugs, through a mechanism termed 
“ion trapping”, and based on ion protonation of drugs 
[99–102]. Thus, the reversion of this pH gradient may 
strongly facilitate the successful treatment. Indeed, sev-
eral in vitro and in vivo studies show that low pH reduces 
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uptake and efficacy of weak base chemotherapeutics, such 
as anthracyclines (e.g., doxorubicin), anthraquinones (e.g., 
mitoxantrone), and vinca alkaloids (e.g., vincristine and 
vinblastine) [101, 103]. On the contrary, alkalization of 
extracellular environment enhances intracellular accumu-
lation and cytotoxicity of some of these weak base drugs 
[104]. Accordingly, Wojtkowiak et  al. demonstrated that 
a combined treatment with sodium bicarbonate and doxo-
rubicin reduces more efficiently tumor volume than doxo-
rubicin alone [105], suggesting that alkalization enhances 
doxorubicin efficacy. According to these results, De Milito 
and Fais showed that in vivo oral pretreatment with proton 
pump inhibitors (PPIs) of tumor-bearing animals re-sensi-
tizes tumors to anticancer drugs [106].
Other possible mechanisms working on drug resistance 
in low pH have been described. Among these, it is of a 
great importance the ability of acidic  pHe to increase the 
pump activity of the p-glycoprotein (pGP), a drug efflux 
transporter. Thews et al. observed that acidic prostate car-
cinoma cells express a pGP activity more than doubled of 
that of cells grown in a standard pH medium [107]. These 
authors reported that up-regulation of pGP in acidic cells 
was related to an increased intracellular  Ca2+ level, stimu-
lated by a protein kinase C activity [107]. It has also been 
observed that acidosis-induced pGP activity may be related 
to ERK and p38 pathways. The inhibition of both ERK and 
p38 abolished acidosis-induced daunorubicin efflux and 
re-establish daunorubicin sensitivity in rat prostate cancer 
cells [108]. Moreover, acidosis of the extracellular milieu 
may interfere in drug efficacy inducing a cell quiescence, 
namely, inducing a very low proliferative rate, as previously 
discussed [35, 97, 109]. It is known that cells are more sen-
sitive to drugs and radiation therapy when in S-phase than 
in the other cell cycle phases. Tumor pH may also have 
indirect effects on cell sensitivity to drugs; actually, chronic 
exposure to an acidic pH is reported to increase expression 
of heat shock protein HSP27 level in tumor cells, leading to 
resistance to cisplatin [110].
Studying the effects of irradiation on cell killing and 
induction of apoptosis on low pH (pH 6.8) adapted human 
maxillary carcinoma cells, Ohtsubo et al. found that these 
cells, chronically adapted to low pHe, express a radio-
insensitive phenotype [111]. To support this finding, it was 
found that an acidic microenvironment induces p53 expres-
sion [112], suppresses radiation-induced apoptosis [113, 
114], and prolongs radiation-induced G2/M arrest, result-
ing in an increased DNA damage repair during the pro-
longed G2 arrest [115].
On the whole, acidity of extracellular microenvironment 
confers to dormant tumor cells a great advantage sustain-
ing a resistant chemo- and radio-therapy phenotype, and 
treatments aimed to buffer extracellular acidity may revert 
several aggressive properties including resistance to con-
ventional therapy.
Concluding remarks
Acidosis of tumor microenvironment of most solid tumors 
is well ascertained to promote an aggressive, immune-, 
chemo-, and radio-resistant phenotype, and in some cir-
cumstances an EMT program and stemness (Fig. 1). There-
fore, acidic-adapted tumor cells are likely be able to survive 
to endogenous and exogenous stressors and might represent 
a hidden reserve of tumor cells from which a tumor could 
relapse and disseminate. Thus, acidosis of solid tumors may 
acquire a role in generating a novel niche of dormant tumor 
cells. Along with this view, it is reasonable for a success-
ful treatment of cancer to build up new combined strategies 
focused on the inhibition of tumor cell-microenvironment 
crosstalk, and in particular targeting acidosis and acidic-
adapted tumor cells.
Fig. 1  Crosstalk between the 
acidic microenvironment and 
cellular dormancy
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